| Symbol | GANX |
|---|---|
| Name | GAIN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 4800 MONTGOMERY LANE,SUITE 220, BETHESDA, Maryland, 20814, United States |
| Telephone | +1 301 500-1556 |
| Fax | — |
| — | |
| Website | https://www.gaintherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001819411 |
| Description | Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements. Additional info from NASDAQ: |
(30% Negative) GAIN THERAPEUTICS, INC. (GANX) Reports Q2 2026 Financial Results
Read moreGain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
Read moreGain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
Read moreNew Form ARS - Gain Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001104659-26-050437 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - Gain Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001104659-26-050435 <b>Size:</b> 409 KB
Read moreNew Form DEF 14A - Gain Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001104659-26-050431 <b>Size:</b> 1 MB
Read moreGain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
Read moreDirector Mack Gene 🟢 acquired 200.0K shares (1 derivative) of Gain Therapeutics, Inc. (GANX) at $1.86 Transaction Date: Mar 24, 2026 | Filing ID: 035403
Read moreFuggetta Gianluca 🟢 acquired 50.0K shares (1 derivative) of Gain Therapeutics, Inc. (GANX) at $1.86 Transaction Date: Mar 24, 2026 | Filing ID: 035400
Read moreGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07280299 | Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Park… | Phase2 | Parkinson Disease | Not_Yet_Recruiting | 2026-05-30 | 2028-06-30 | ClinicalTrials.gov |
| NCT06732180 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Par… | Phase1 | Parkinson Disease | Recruiting | 2025-02-21 | 2025-11-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| GT-02287 | Other | Phase PHASE1 | Parkinson Disease | RECRUITING | NCT06732180 |
| Placebo | DRUG | Phase PHASE2 | Parkinson Disease | NOT_YET_RECRUITING | NCT07280299 |
| High Dose GT-02287 | DRUG | Phase PHASE2 | Parkinson Disease | NOT_YET_RECRUITING | NCT07280299 |
| Low Dose GT-02287 | DRUG | Phase PHASE2 | Parkinson Disease | NOT_YET_RECRUITING | NCT07280299 |
| GT-02287 | DRUG | Phase PHASE1 | Parkinson Disease | RECRUITING | NCT06732180 |